Leptin and Peptide YY(3-36) are hormones created respectively in fat tissue and the small intestine, and both facilitate satiety and potentially aid long-term weight reduction [12]
GLP-1RAs as a support for MCAS For some basics: glucagon-like peptide-1 receptor agonists (abbreviated as GLP-1 medications or as I noted above, GLP-1RAs) are a class of medications that includes semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound, which also work on GIP receptors), as well as in-trials Retatrutide (a triple agonist that works on GLP-1, GIP, and Glucagon receptors)
Clinical research has shown that semaglutide can lead to significant weight reduction, with many patients losing 10-15% of their body weight
This is relevant to our studies with exendin-asp3, for which differences in loss of surface GLP-1R vs
During perimenopause and menopause, this decline accelerates due to hormonal changes, making supplementation even more crucial